Cut the Cost of Doing Business 

Past Weekly Updates

• October 10, 2011
• October 3, 2011
• September 26, 2011
• September 19, 2011 
• September 12, 2011 
• September 7, 2011

January 23 - 24, 2012

Computer History Museum, Silicon Valley 

SoCalBio By-Invitation-Only Events

Thanks to Attendees of the SoCalBio Women, Work & Wisdom (W3) Inaugural Group Meeting in Los Angeles

  W3 Chair, Diane Palumbo of MannKind Corp. greets attendees at the House Research Institute. W3 is a SoCalBio group created recently to empower bioscience women entrepreneurs and executives in Southern California. Join W3 on LinkedIn at:  http://www.linkedin.com/groups?mostPopular=&gid=3922809

SoCalBio Conference 

23 Days Left

Reserve Your Seat to Interface With Emerging Southern California-Based Biotech and Medical Device Companies

Click here to see an updated list of companies

selected to date 

Sponsorship opportunities available 

Thanks to SoCalBio Partners

Business Mixer 

RSVP for the SoCalBio Business Mixer in 

Orange County

"Neuroscience Innovations:  

What Is Coming Down the Pike"  

Thursday, October 20, 2011 from 7:00 AM to 9:30 AM (PT)

Irvine, CA | UCI University Club

Presentations

• "Researching Ways to Make Memories Last a Lifetime," by Frank LaFerla, PhD, Department of Neurobiology & Behavior, UCI
• "Managing Tinnitus and Hearing Loss Via the Web," by Hamid Djalilian, MD, Department of Otolaryngology/Head & Neck Surgery, UCI
• "Wearable Devices for Movement Monitoring and Therapy," by Nizan Friedman, Biorobotics Laboratory and Calit2, UCI

Genomics 2.0: Ten Years After the Bubble, it's Getting Really Interesting Again

The headlines from just the last couple weeks in genomics are jaw-dropping. Experiments are being announced almost every week which would have been unimaginable even a year ago when sequencing a whole genome cost around $10,000. Suddenly an individual's entire genome, the complete 6 billion letter signature of DNA units in each human, can be had for $4,000 or less, in a few weeks. And that has enabled scientists and business people to dream some pretty big dreams ... Read more

Venture Capital Increases its Funding of Medical Device Companies.

Venture financing of U.S. life sciences firms bucked the trend in the third quarter of 2011 as medical device firms raised close to 47 percent of the total capital invested in private life sciences companies. September helped, with twice as much invested in medical device companies as in biotechnology firms. Of the total $631.4 million invested, $396.3 million, or 62.8 percent, went to medical device developers ... Read more

Caltech Researchers Develop ePetri: a Smartphone-Based Petri Dish

Engineers from the California Institute of Technology (CalTech) have unveiled the ePetri dish: a small, lens-free microscopy imaging platform.  The prototype was built using a smartphone, a commercially available cell-phone image sensor and Lego building blocks. The device is described in this week's Proceedings of the National Academy of Sciences (PNAS)... Read more 

Amgen Signals Looming Restructuring

of R&D Operations

Amgen's $3 billion R&D operation is in for some changes. In a move analysts see as a likely herald of budget cuts, the company alerted its research staff that the world's biggest biotech was pondering ways "to improve focus and to re-allocate resources to key pipeline assets and activities." Now all they have to do is wait until Amgen's Q3 earnings call on October 24 to find out how they fit into this reconfigured R&D arm... Read more

ISTA Pharmaceuticals Announces Statistically Significant Phase 3 Results for PROLENSA

PROLENSA is a low concentration of bromfenac in a modified ophthalmic solution developed to treat pain and inflammation associated with cataract surgery. In both Phase 3 studies, PROLENSA was statistically significantly better than placebo and met the primary efficacy endpoint of absence of ocular inflammation 14 days following surgery and the secondary efficacy endpoint of elimination of ocular pain one day post-surgery... Read more

Amgen Appoints President & COO Robert Bradway to the Company's Board of Directors

Amgen announced last week that its Board of Directors has appointed Robert A. Bradway to the Company's Board.  Bradway, 48, is Amgen's president and chief operating officer. The addition of Bradway brings the number of Amgen board members to 13... Read more

 Nanogea (Culver City)

• Scientist

Neomend (Irvine)

• Principal Mechanical Engineer 

Replenish (Pasadena)

• Test Engineer 
• Administrative Assistant 
• CAD Product Developer 

Boston Scientific Neuromodulation (Valencia)

• Strategic Marketing Mgr 
• Sr Product Mgr DBS 
• Sr Product Mgr 
• Marketing Communication Mgr 

Kinamed (Camarillo)

•  International Regulatory Affairs Associate 

•  Entry-Level Marketing 

•  Western Region Sales Manager